DLA Piper supports national and international pharmaceutical and medical device companies in market launches, IP law, medical device law, compliance and distribution law as well as contract-related matters. The team boasts expertise in the private equity sector and regularly advises on investments and is well positioned for cross-border transactions. The practice regularly cooperates with the in 2023 newly-formed EU life sciences regulatory team from the Brussels location and has since been led by Kokularajah Paheenthararajah, who covers regulatory and patent law matters pertaining to cell and gene therapies, precision pharmaceuticals and diagnostics.
Testimonials
Collated independently by Legal 500 research team.
'High level of competence, fast reaction times, flexible and creative in finding new solutions.'
'Moritz von Hesberg: Comprehensively informed, very analytical and reliable, balanced and well-balanced communication with the opposing side. Communicative and technically adept, even in interfacing areas. Fast reaction times, approachable and available at all times.'
'Our collaboration with Moritz von Hesberg is unique. We benefit enormously from the expertise of the lawyer and his team and their ability to react extremely quickly. The advice is holistic in the best sense of the word.'